Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)
NCT ID: NCT05116189
Last Updated: 2025-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
643 participants
INTERVENTIONAL
2021-12-13
2028-10-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
NCT05310344
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT03029403
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT00063401
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT04498117
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab + paclitaxel ± bevacizumab
Participants receive pembrolizumab 400 mg via intravenous (IV) infusion for eighteen 6-week cycles (approximately 2 years) PLUS paclitaxel 80 mg/m\^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 every 3 weeks \[Q3W\]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.
Pembrolizumab
IV infusion
Paclitaxel
IV infusion
Bevacizumab
IV infusion
Docetaxel
IV infusion
Placebo + paclitaxel ± bevacizumab
Participants receive placebo via IV infusion for eighteen 6-week cycles (approximately 2 years) PLUS paclitaxel 80 mg/m\^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 every 3 weeks \[Q3W\]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.
Paclitaxel
IV infusion
Bevacizumab
IV infusion
Placebo for pembrolizumab
IV infusion
Docetaxel
IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pembrolizumab
IV infusion
Paclitaxel
IV infusion
Bevacizumab
IV infusion
Placebo for pembrolizumab
IV infusion
Docetaxel
IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has received 1 or 2 prior lines of systemic therapy for ovarian cancer (OC), including at least 1 prior platinum-based therapy. Participants may have received a prior poly (ADP-ribose) polymerase inhibitor (PARPi), anti-PD-1/anti-PD-L1 therapy, bevacizumab, or hormonal therapy; these will not be considered a separate line of therapy. Any chemotherapy regimen change due to toxicity in the absence of disease progression will be considered part of the same line of therapy.
* Has provided documented informed consent for the study.
* Has radiographic evidence of disease progression within 6 months (180 days) after the last dose of platinum-based chemotherapy for OC (i.e., platinum-resistant disease).
* Is a candidate for paclitaxel chemotherapy (and bevacizumab, if using).
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 3 days before randomization.
* For a female participant, she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP and uses a contraceptive method that is highly effective (with a failure rate of \<1% per year).
* Has radiographically evaluable disease, either measurable or nonmeasurable per RECIST 1.1, as assessed by the local site investigator.
* Archival tumor tissue sample or newly obtained core or incisional/excisional biopsy of a tumor lesion not previously irradiated has been provided.
* Have adequate organ function.
Exclusion Criteria
* Has primary platinum-refractory disease, defined as disease that has progressed per radiographic imaging while receiving or within 28 days of the last dose of first-line platinum-based therapy.
* Has prior disease progression on weekly paclitaxel alone.
* Has received \>2 prior lines of systemic therapy for OC.
* Has received prior systemic anticancer therapy including investigational agents or maintenance therapy (including bevacizumab maintenance therapy), within 4 weeks before randomization.
* Has received prior radiation therapy within 2 weeks of start of study intervention.
* Has not recovered adequately from surgery and/or any complications from the surgery.
* Has received colony-stimulating factors (e.g., granulocyte colony-stimulating factor \[G-CSF\], granulocyte-macrophage colony-stimulating factor,\[GM-CSF\] or recombinant erythropoietin) within 4 weeks before randomization.
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
* Has received investigational agent or has used an investigational device within 4 weeks prior to study intervention.
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Has severe hypersensitivity (≥Grade 3) to pembrolizumab, paclitaxel, or bevacizumab (if using) and/or any of their excipients.
* Has an active autoimmune disease that has required systemic treatment in the past 2 years.
* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
* Has an active infection requiring systemic therapy.
* Has a known history of human immunodeficiency virus (HIV) infection.
* Has a known history of Hepatitis B or known active Hepatitis C virus infection.
* Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.
* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
* Participant, in the judgement of the investigator, is unlikely to comply with the study procedures, restrictions, and requirements of the study.
* Has had an allogenic tissue/solid organ transplant.
For bevacizumab treatment
* Has uncontrolled hypertension.
* Has current, clinically relevant bowel obstruction including related to underlying epithelial OC, abdominal fistula or gastrointestinal perforation, intra-abdominal abscess, or evidence of rectosigmoid involvement by pelvic exam.
* Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before randomization.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HonorHealth ( Site 0041)
Phoenix, Arizona, United States
Marin Cancer Care ( Site 0055)
Greenbrae, California, United States
Pacific Cancer Care ( Site 0028)
Monterey, California, United States
Eisenhower Medical Center ( Site 0067)
Rancho Mirage, California, United States
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0004)
New Haven, Connecticut, United States
University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 0054
Gainesville, Florida, United States
Sarasota Memorial Hospital ( Site 0018)
Sarasota, Florida, United States
Moffitt Cancer Center ( Site 0033)
Tampa, Florida, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0005)
Marietta, Georgia, United States
Advocate Medical Group-Oncology ( Site 0049)
Park Ridge, Illinois, United States
Parkview Research Center at Parkview Regional Medical Center ( Site 0027)
Fort Wayne, Indiana, United States
St. Vincent Hospital and Health Care Center, Inc ( Site 0032)
Indianapolis, Indiana, United States
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0040)
Edgewood, Kentucky, United States
WK Physicians Network / Hematology Oncology Associates ( Site 0034)
Shreveport, Louisiana, United States
Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0015)
Baltimore, Maryland, United States
University of Massachusetts Chan Medical School-Division of Gynecologic Oncology ( Site 0003)
Worcester, Massachusetts, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0007)
Hackensack, New Jersey, United States
Roswell Park Cancer Institute ( Site 0039)
Buffalo, New York, United States
Columbia University Medical Center ( Site 0010)
New York, New York, United States
Novant Health Presbyterian Medical Center ( Site 0029)
Charlotte, North Carolina, United States
Duke Cancer Institute ( Site 0038)
Durham, North Carolina, United States
Novant Health Forsyth Medical Center ( Site 0057)
Winston-Salem, North Carolina, United States
Aultman Hospital-Oncology Clinical Trials ( Site 0009)
Canton, Ohio, United States
MetroHealth Medical Center-Cancer Care Center ( Site 0047)
Cleveland, Ohio, United States
Providence Portland Medical Center ( Site 0048)
Portland, Oregon, United States
University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0024)
Pittsburgh, Pennsylvania, United States
Sanford Cancer Center ( Site 0064)
Sioux Falls, South Dakota, United States
The West Clinic, PLLC dba West Cancer Center ( Site 0058)
Germantown, Tennessee, United States
Texas Oncology - Dallas (Presbyterian) ( Site 0065)
Dallas, Texas, United States
Texas Oncology - The Woodlands_Lee ( Site 0043)
The Woodlands, Texas, United States
Inova Schar Cancer Institute ( Site 0019)
Fairfax, Virginia, United States
Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)
Westmead, New South Wales, Australia
Gallipoli Medical Research Foundation-GMRF CTU ( Site 0202)
Brisbane, Queensland, Australia
Epworth Freemasons ( Site 0204)
Melbourne, Victoria, Australia
St. John of God Subiaco Hospital ( Site 0203)
Subiaco, Western Australia, Australia
Institut Jules Bordet-Medicine Oncology ( Site 0302)
Brussels, Bruxelles-Capitale, Region de, Belgium
UZ Gent-Medical oncology ( Site 0301)
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven ( Site 0303)
Leuven, Vlaams-Brabant, Belgium
AZ Groeninge Campus Kennedylaan-Oncology ( Site 0305)
Kortrijk, West-Vlaanderen, Belgium
Hospital Araújo Jorge ( Site 0401)
Goiânia, Goiás, Brazil
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0404)
Natal, Rio Grande do Norte, Brazil
ANIMI - Unidade de Tratamento Oncologico ( Site 0408)
Lages, Santa Catarina, Brazil
BP - A Beneficencia Portuguesa de São Paulo ( Site 0403)
São Paulo, São Paulo, Brazil
Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0405)
São Paulo, São Paulo, Brazil
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA-Pesquisa Clinica HC II ( Site 0402)
Rio de Janeiro, , Brazil
Tom Baker Cancer Center ( Site 0511)
Calgary, Alberta, Canada
BC Cancer Abbotsford ( Site 0512)
Abbotsford, British Columbia, Canada
BC Cancer Victoria ( Site 0513)
Victoria, British Columbia, Canada
Kingston Health Sciences Centre-Kingston General Hospital Si-Oncology and/or Hematology - Gynecolog
Kingston, Ontario, Canada
Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0508)
Toronto, Ontario, Canada
CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0501)
Montreal, Quebec, Canada
Jewish General Hospital ( Site 0505)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 0502)
Montreal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
Québec, Quebec, Canada
Saskatoon Cancer Center ( Site 0510)
Saskatoon, Saskatchewan, Canada
Clínica Puerto Montt ( Site 0601)
Port Montt, Los Lagos Region, Chile
Oncovida ( Site 0603)
Santiago, Region M. de Santiago, Chile
Instituto de Radiomedicina-hemato-oncologia ( Site 0604)
Santiago, Region M. de Santiago, Chile
Clínica Vespucio-Hemato - Ocology ( Site 0607)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0609)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0605)
Santiago, Region M. de Santiago, Chile
James Lind Centro de Investigación del Cáncer ( Site 0602)
Temuco, Región de la Araucanía, Chile
CIDO SpA-Oncology ( Site 0608)
Temuco, Región de la Araucanía, Chile
Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 0709)
Hefei, Anhui, China
Beijing Cancer hospital ( Site 0711)
Beijing, Beijing Municipality, China
Beijing Peking Union Medical College Hospital-Gynecological center of tumor ( Site 0702)
Beijing, Beijing Municipality, China
Fujian Provincial Cancer Hospital ( Site 0713)
Fuzhou, Fujian, China
Lanzhou university second hospital ( Site 0734)
Lanzhou, Gansu, China
Zhujiang Hospital ( Site 0739)
Guangzhou, Guangdong, China
Affiliated Hospital of Guangdong Medical University ( Site 0743)
Zhanjiang, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital ( Site 0717)
Nanning, Guangxi, China
Hainan General Hospital ( Site 0736)
Haikou, Hainan, China
Henan Cancer Hospital ( Site 0718)
Zhengzhou, Henan, China
Wuhan Union Hospital-Medical Oncology ( Site 0735)
Wuhan, Hubei, China
Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 0708)
Wuhan, Hubei, China
Xiangya Hospital Central South University-Gynecology ( Site 0705)
Changsha, Hunan, China
Hunan Cancer Hospital ( Site 0704)
Changsha, Hunan, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (
Nanjing, Jiangsu, China
Zhongda Hospital Southeast University ( Site 0723)
Nanjing, Jiangsu, China
Jiangxi Maternal and Child Health Hospital-Oncology Department ( Site 0716)
Nanchang, Jiangxi, China
The First Hospital of Jilin University ( Site 0710)
Changchun, Jilin, China
Shandong Cancer Hospital-Oncology Department ( Site 0733)
Jinan, Shandong, China
LinYi Cancer Hospital ( Site 0731)
Linyi, Shandong, China
Obstetrics & Gynecology Hospital of Fudan University ( Site 0715)
Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center-Gynecologic Oncology Department ( Site 0701)
Shanghai, Shanghai Municipality, China
Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 0744)
Shanghai, Shanghai Municipality, China
West China Second University Hospital Sichuan University ( Site 0740)
Chengdu, Sichuan, China
Tianjin Central Hosptial of Gynecology Obstetrics ( Site 0737)
Tianjin, Tianjin Municipality, China
Tianjin Medical University Cancer Institute and Hospital ( Site 0720)
Tianjin, Tianjin Municipality, China
Yunnan Province Cancer Hospital-Gynecology Department ( Site 0714)
Kunming, Yunnan, China
The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0741)
Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0706)
Wenzhou, Zhejiang, China
Fundación Colombiana de Cancerología Clínica Vida ( Site 0808)
Medellín, Antioquia, Colombia
Clinica de la Costa LTDA-Clinical Research Oncology & Hematology -Pediatric ( Site 0809)
Barranquilla, Atlántico, Colombia
Clínica Universitaria Colombia ( Site 0806)
Bogotá, Bogota D.C., Colombia
Oncologos del Occidente ( Site 0807)
Pereira, Risaralda Department, Colombia
Hemato Oncologos SA ( Site 0801)
Cali, Valle del Cauca Department, Colombia
Aalborg Universitetshospital, Syd ( Site 0901)
Aalborg, North Denmark, Denmark
Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1001)
Turku, Southwest Finland, Finland
Centre Hospitalier Régional Universitaire de Brest - Hôpital-Institut de cancérologie et hématologi
Brest, Brittany Region, France
Centre François Baclesse-Recherche clinique ( Site 2904)
Caen, Calvados, France
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren-oncologie ( Site 2907)
Limoges, Haute-Vienne, France
Institut Curie - site Saint-Cloud ( Site 2909)
Saint-Cloud, Hauts-de-Seine, France
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 2901)
Rennes, Ille-et-Vilaine, France
Centre de Cancérologie du Grand Montpellier ( Site 2908)
Montpellier, Languedoc-Roussillon, France
Hôpital privé du Confluent SAS-Service d'oncologie médicale ( Site 2905)
Nantes, Loire-Atlantique, France
Universitaetsklinikum Erlangen-Klinik für Gynäkologie und Geburtshilfe ( Site 1205)
Erlangen, Bavaria, Germany
Universitätsklinikum Bonn-Gynaecological oncology ( Site 1203)
Bonn, North Rhine-Westphalia, Germany
Universitaetsklinikum Duesseldorf-Klinik für Frauenheilkunde & Geburtshilfe ( Site 1204)
Düsseldorf, North Rhine-Westphalia, Germany
Zentrum fuer ambulante gynaekologische Onkologie (ZAGO) ( Site 1207)
Krefeld, North Rhine-Westphalia, Germany
CaritasKlinikum Saarbrücken St. Theresia ( Site 1211)
Saarbrücken, Saarland, Germany
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur
Dresden, Saxony, Germany
Universitätsklinikum Leipzig-Department of Gynecology and Obstetrics ( Site 1213)
Leipzig, Saxony, Germany
Charité Campus Virchow-Klinikum ( Site 1201)
Berlin, , Germany
Asklepios Kliniken Hamburg-Asklepios Klinik Barmbek ( Site 1214)
Hamburg, , Germany
St. James's Hospital-Cancer clinical trials office ( Site 2821)
Dublin, , Ireland
Emek Medical Center-Gyn-Onc ( Site 1406)
Afula, , Israel
Soroka Medical Center ( Site 1404)
Beersheba, , Israel
Rambam Health Care Campus-Gyneco-oncology unit ( Site 1402)
Haifa, , Israel
Shaare Zedek Medical Center ( Site 1405)
Jerusalem, , Israel
Rabin Medical Center ( Site 1401)
Petah Tikva, , Israel
Sheba Medical Center ( Site 1407)
Ramat Gan, , Israel
Sourasky Medical Center ( Site 1403)
Tel Aviv, , Israel
IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1501)
Bologna, Emilia-Romagna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1503)
Milan, Lombardy, Italy
Ospedale San Gerardo-ASST Monza-Oncologia ( Site 1508)
Monza, Lombardy, Italy
ASST Grande Ospedale Metropolitano Niguarda ( Site 1505)
Milan, Milano, Italy
Ospedale Mauriziano-Ginecologia e Ostetricia ( Site 1507)
Turin, Piedmont, Italy
Azienda Ospedaliera Spedali Civili di Brescia ( Site 1504)
Brescia, , Italy
Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 1502)
Milan, , Italy
Aichi Cancer Center Hospital ( Site 1610)
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East ( Site 1609)
Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center ( Site 1603)
Matsuyama, Ehime, Japan
Ehime University Hospital ( Site 1606)
Tōon, Ehime, Japan
Kurume University Hospital ( Site 1607)
Kurume, Fukuoka, Japan
Hokkaido University Hospital ( Site 1604)
Sapporo, Hokkaido, Japan
Iwate Medical University Hospital ( Site 1613)
Shiwa-gun Yahaba-cho, Iwate, Japan
Nippon Medical School Musashi Kosugi Hospital ( Site 1614)
Kawasaki, Kanagawa, Japan
Saitama Medical University International Medical Center ( Site 1601)
Hidaka-shi, Saitama, Japan
Shizuoka Cancer Center ( Site 1611)
Nakatogari, Shizuoka, Japan
National Cancer Center Hospital ( Site 1612)
Chuo-ku, Tokyo, Japan
Japanese Foundation for Cancer Research ( Site 1605)
Koto, Tokyo, Japan
Osaka International Cancer Institute ( Site 1602)
Osaka, , Japan
Investigación Oncofarmacéutica-Investigación clínica ( Site 1706)
La Paz, Baja California Sur, Mexico
COI Centro Oncologico Internacional S.A.P.I. de C.V.-Investigation Unit COI ( Site 1703)
Mexico City, Mexico City, Mexico
INSTITUTO NACIONAL DE CANCEROLOGIA ( Site 1701)
Mexico City, Mexico City, Mexico
iCan Oncology Center Centro Medico AVE ( Site 1704)
Monterrey, Nuevo León, Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 1705)
Oaxaca City, , Mexico
Radboudumc ( Site 1802)
Nijmegen, Gelderland, Netherlands
Leids Universitair Medisch Centrum-Medical Oncology ( Site 1801)
Leiden, South Holland, Netherlands
Erasmus Medisch Centrum-Medical Oncology ( Site 1803)
Rotterdam, South Holland, Netherlands
Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1804)
Utrecht, , Netherlands
Auckland City Hospital ( Site 1901)
Auckland, , New Zealand
Universitetssykehuset Nord-Norge HF-Kreftavdelingen ( Site 2001)
Tromsø, Troms, Norway
Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit
Poznan, Greater Poland Voivodeship, Poland
Szpital Kliniczny im. Księżnej Anny Mazowieckiej ( Site 2103)
Warsaw, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Gynecological Oncology Department ( Sit
Warsaw, Masovian Voivodeship, Poland
Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2106)
Bialystok, Podlaskie Voivodeship, Poland
Uniwersytecki Szpital Kliniczny w Bialymstoku-Uniwersyteckie Centrum Onkologii ( Site 2104)
Bialystok, Podlaskie Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi
Gdansk, Pomeranian Voivodeship, Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 21
Gliwice, Silesian Voivodeship, Poland
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2107)
Kielce, Świętokrzyskie Voivodeship, Poland
Chelyabinsk Regional Clinical Oncology Dispensary-Chelyabinsk Regional Clinical Oncology Dispensary
Chelyabinsk, Chelyabinsk Oblast, Russia
Ogarev Mordovia State University ( Site 2209)
Saransk, Mordoviya, Respublika, Russia
Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF-Chemotherapy #2 ( Site 2211)
Moscow, Moscow, Russia
Moscow City Oncology Hospital #62 ( Site 2214)
Krasnogorsk D-t, Moscow Oblast, Russia
SVERDLOVSK REGIONAL ONCOLOGY DISPENSARY-Oncogynecology Department ( Site 2216)
Yekaterinburg, Sverdlovsk Oblast, Russia
Seoul National University Hospital ( Site 2302)
Seoul, , South Korea
Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 2303)
Seoul, , South Korea
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 2304)
Seoul, , South Korea
Gangnam Severance Hospital ( Site 2301)
Seoul, , South Korea
cukurova universty ( Site 2706)
Sarçam, Adana, Turkey (Türkiye)
Istanbul Universitesi Cerrahpasa ( Site 2709)
Fatih, Istanbul, Turkey (Türkiye)
Ege University Medicine of Faculty ( Site 2702)
Bornova, İzmir, Turkey (Türkiye)
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2704)
Adana, , Turkey (Türkiye)
Ankara University Hospital Cebeci ( Site 2701)
Ankara, , Turkey (Türkiye)
Baskent Universitesi Ankara Hastanesi ( Site 2707)
Ankara, , Turkey (Türkiye)
Bezmialem Vakf Üniversitesi-Oncology ( Site 2705)
Istanbul, , Turkey (Türkiye)
T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma
Istanbul, , Turkey (Türkiye)
Brighton and Sussex University Hospitals NHS Trust ( Site 2803)
East Sussex, Brighton And Hove, United Kingdom
Addenbrooke's Hospital ( Site 2808)
Cambridge, Cambridgeshire, United Kingdom
The Royal Cornwall Hospital ( Site 2804)
Truro, Cornwall, United Kingdom
Westmorland General Hospital ( Site 2815)
Kendal, Cumbria, United Kingdom
Ninewells Hospital and Medical School ( Site 2826)
Dundee, Dundee City, United Kingdom
Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 2812)
Leicester, England, United Kingdom
Hammersmith Hospital-Medical Oncology ( Site 2818)
London, London, City of, United Kingdom
Velindre Cancer Centre ( Site 2805)
Cardiff, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-3475-B96
Identifier Type: OTHER
Identifier Source: secondary_id
KEYNOTE-B96
Identifier Type: OTHER
Identifier Source: secondary_id
ENGOT-ov65
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2051210184
Identifier Type: REGISTRY
Identifier Source: secondary_id
2023-506177-35-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1287-5318
Identifier Type: REGISTRY
Identifier Source: secondary_id
2020-005027-37
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
3475-B96
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.